Citations

Mayo Clinic

Showing 10 of 108551 citations.

Faculty Opinions recommendation of Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
Fernández-Zapico, Martín E.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 15, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725876995.793513150 Get It

Faculty Opinions recommendation of Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.
Fernández-Zapico, Martín E.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 15, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725623981.793513151 Get It

Laparoscopic Distal Pancreatectomy and Splenectomy for Insulinoma
Morris, Jacob, Truty, Mark J. , McKenzie, Travis J.

VideoEndocrinology | January 15, 2016 | Volume: 2 | Issue: 1 | Pages: No page available

10.1089/ve.2014.0037 Get It

Introduction to Ultrasound-Guided Fine-Needle Aspiration of the Thyroid
Bernet, Victor , Stancampiano, Fernando F.

VideoEndocrinology | January 15, 2016 | Volume: 1 | Issue: 1 | Pages: No page available

10.1089/ve.2014.0003 Get It

Concordant and Discordant Cardiac Magnetic Resonance Imaging Delayed Hyperenhancement Patterns in Patients with Ischemic and Non-Ischemic Cardiomyopathy
Kim, Eun Kyoung , Chang, Sung‐A , Choi, Jin‐Oh , Glockner, James F., Shapiro, Brian P. , Jang, Shin Yi , Kim, Sung Mok , Oh, Jae K. , Glockner, James, Fine, Nowell, Miller, Wayne, Choe, Yeon Hyeon , Fine, Nowell Mark , Miller, Wayne L. , Lee, Sang‐Chol

Korean Circulation Journal | January 15, 2016 | Volume: 46 | Issue: 1 | Pages: 41

10.4070/kcj.2016.46.1.41 | PMID 26798384 Get It

Quantitative Imaging in Cancer Clinical Trials
Yankeelov, Thomas E. , Mankoff, David A. , Schwartz, Lawrence H., Lieberman, Frank S. , Buatti, John M. , Mountz, James M. , Fennessy, Fiona M., Kalpathy–Cramer, Jayashree , Wahl, Richard L. , Kinahan, Paul E. , Zhao, Binsheng , Gillies, Robert J. , Clarke, Laurence P. , Nordstrom, Robert J. , Erickson, Bradley J. , Huang, Wei , Linden, Hannah M. , Hylton, Nola M. , Rubin, Daniel L. , Buatti, John M , Wahl, Richard L , Mankoff, David A

Clinical Cancer Research | January 15, 2016 | Volume: 22 | Issue: 2 | Pages: 284-290

10.1158/1078-0432.ccr-14-3336 | PMID 26773162 Get It

Abstract As anticancer therapies designed to target specific molecular pathways have been developed, it has become critical to develop methods to assess the response induced by such agents. Although traditional, anatomic CT, and MRI examinations are useful in many settings, increasing evidence suggests that these methods cannot answer the fundamental biologic and physiologic questions essential for assessment and, eventually, prediction of treatment response in the clinical trial setting, especially in the critical period soon after treatment is initiated. To optimally apply advances in quantitative imaging methods to trials of targeted cancer therapy, new infrastructure improvements are needed that incorporate these emerging techniques into the settings where they are most likely to have impact. In this review, we first elucidate the needs for therapeutic response assessment in the era of molecularly targeted therapy and describe how quantitative imaging can most effectively provide scientifically and clinically relevant data. We then describe the tools and methods required to apply quantitative imaging and provide concrete examples of work making these advances practically available for routine application in clinical trials. We conclude by proposing strategies to surmount barriers to wider incorporation of these quantitative imaging methods into clinical trials and, eventually, clinical practice. Our goal is to encourage and guide the oncology community to deploy standardized quantitative imaging techniques in clinical trials to further personalize care for cancer patients and to provide a more efficient path for the development of improved targeted therapies. Clin Cancer Res; 22(2); 284–90. ©2016 AACR.
Overcoming Weight Bias in the Management of Patients With Diabetes and Obesity
Puhl, Rebecca M. , Nadglowski, Joseph , Phelan, Sean M. , Kyle, Theodore K.

Clinical Diabetes | January 15, 2016 | Volume: 34 | Issue: 1 | Pages: 44-50

10.2337/diaclin.34.1.44 | PMID 26807008 Get It

Case-Based Review: meningioma
Fogh, Shannon , Barker, Fred G., Brastianos, Priscilla K. , Clarke, Jennifer , Oberndorfer, Stephan, Preusser, Matthias , Raghunathan, Aditya , Santagata, Sandro , Theodosopoulos, Philip V. , Fogh, Shannon E, Clarke, Jennifer L, Johnson, Derek R. , Kaufmann, Timothy J. , Santagata, Sandro , Raghunathan, Aditya , Preusser, Matthias

Neuro-Oncology Practice | January 15, 2016 | Volume: 3 | Issue: 2 | Pages: 120-134

10.1093/nop/npv063 | PMID 31386096 Get It

AbstractMeningioma is by far the most common primary intracranial tumor in adults. Treatment of meningioma is complex due to a tremendous amount of variability in tumor behavior. Many patients are incidentally found to have tumors that will remain asymptomatic throughout their lives. It is important to identify these patients so that they can be spared from potentially morbid interventions. On the other end of the spectrum, high-grade meningiomas can behave very aggressively. When treatment is necessary, surgical resection is the cornerstone of meningioma therapy. Studies spanning decades have demonstrated that extent of resection correlates with prognosis. Radiation therapy, either in the form of external beam radiation therapy or stereotactic radiosurgery, represents another important therapeutic tool that can be used in place of or as a supplement to surgery. There are no chemotherapeutic agents of proven efficacy against meningioma, and chemotherapy treatment is generally reserved for patients who have exhausted surgical and radiotherapy options. Ongoing and future studies will help to answer unresolved questions such as the optimum use of radiation in resected WHO grade II meningiomas and the efficacy of additional chemotherapy agents.
Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman
King, Rebecca L. , Howard, Matthew T.

Blood | January 15, 2016 | Volume: 127 | Issue: 2 | Pages: 268-268

10.1182/blood-2015-10-674945 | PMID 28837310 Get It

Modeling the Cost‐Effectiveness of Doula Care Associated with Reductions in Preterm Birth and Cesarean Delivery
Alarid‐Escudero, Fernando , Vogelsang, Carrie A., Blauer‐Peterson, Cori, Howell, Elizabeth A. , Hardeman, Rachel R. , Kozhimannil, Katy B.

Birth | January 14, 2016 | Volume: 43 | Issue: 1 | Pages: 20-27

10.1111/birt.12218 | PMID 26762249 Get It

AbstractBackgroundOne in nine US infants is born before 37 weeks' gestation, incurring medical costs 10 times higher than full‐term infants. One in three infants is born by cesarean; cesarean births cost twice as much as vaginal births. We compared rates of preterm and cesarean birth among Medicaid recipients with prenatal access to doula care (nonmedical maternal support) with similar women regionally. We used data on this association to mathematically model the potential cost‐effectiveness of Medicaid coverage of doula services.MethodsData came from two sources: all Medicaid‐funded, singleton births at hospitals in the West North Central and East North Central US (n = 65,147) in the 2012 Nationwide Inpatient Sample, and all Medicaid‐funded singleton births (n = 1,935) supported by a community‐based doula organization in the Upper Midwest from 2010 to 2014. We analyzed routinely collected, de‐identified administrative data. Multivariable regression analysis was used to estimate associations between doula care and outcomes. A probabilistic decision‐analytic model was used for cost‐effectiveness estimates.ResultsWomen who received doula support had lower preterm and cesarean birth rates than Medicaid beneficiaries regionally (4.7 vs 6.3%, and 20.4 vs 34.2%). After adjustment for covariates, women with doula care had 22 percent lower odds of preterm birth (AOR 0.77 [95% CI 0.61–0.96]). Cost‐effectiveness analyses indicate potential savings associated with doula support reimbursed at an average of $986 (ranging from $929 to $1,047 across states).ConclusionsBased on associations between doula care and preterm and cesarean birth, coverage reimbursement for doula services would likely be cost saving or cost‐effective for state Medicaid programs.